Development of an Ad5-CEA/Brachyury Vector Approach for Cancer Treatment

DESCRIPTION (provided by applicant): With the discovery of new biomarkers associated with tumor development, many of these tumor-associated antigens (TAA) are being utilized in immunotherapeutic modalities designed to induce anti-tumor directed cytotoxicimmune responses. It is increasingly clear that not any one of these TAA is sufficient, as a single entity to develop an immunotherapeutic treatment agent. Consequently, our efforts are being focused on developing multi-targeted immunotherapeutic approachagainst TAA. The overall goal of the current project is to expand our immunotherapeutic approach for the treatment of metastatic colorectal cancer (mCRC) using a multiple targeted approach. Drs. Jeffery Schlom and James Gully at the National Cancer Institute have agreed to collaborate with us to reach this goal. We have achieved safety, dose response, and an increased overall survival in mCRC patients using our Ad5 [E1-, E2b-]-CEA(6D) (ETBX-011) immunotherapeutic as a single agent. We believe that addi